Related Experiment Videos
[Treatment of primary tuberculosis in children]
1Hôpital Robert-Debré, Paris, France.
Insights
Rising tuberculosis cases necessitate improved screening and treatment. BCG vaccination and accurate Mantoux tests are key for prevention, with distinct therapeutic approaches for latent versus patent tuberculosis.
Area of Science:
- Public Health
- Infectious Diseases
- Pediatrics
Context:
- Increasing global prevalence of tuberculosis (TB).
- Need for rigorous screening and treatment protocols for primary TB.
- Importance of preventive measures like BCG vaccination.
Purpose:
- To outline current recommendations for screening and treatment of primary tuberculosis.
- To differentiate management strategies for latent versus patent TB in children.
- To highlight the role of specific drug regimens and adjunctive therapies.
Summary:
- BCG vaccination and precise Mantoux testing are crucial for TB prevention and screening.
- Latent tuberculosis management involves a 6-month, two-drug therapy (isoniazid, rifampicin).
- Patent tuberculosis requires a 4-drug regimen initially (isoniazid, rifampicin, ethambutol, pyrazinamide), followed by a 2-drug regimen, with corticosteroids for specific complications.
Impact:
- Provides evidence-based guidelines for clinicians managing pediatric TB.
- Aims to improve patient outcomes through optimized treatment strategies.
- Contributes to public health efforts in controlling TB transmission and morbidity.
Abstract:
The increased prevalence of tuberculosis during the past years incites to a rigorous attitude in screening and treatment of primary tuberculosis. The authors underlines the importance of the prevention by BCG vaccination and of careful screening using correctly performed Mantoux test. The treatment of primary tuberculosis is different whether it is latent (tuberculin positive children without evidence of disease) or patent (with clinical or radiological signs, mycobacterium tuberculosis identification). For latent tuberculosis a two drugs therapy with isoniazid an rifampicine during 6 months is recommended. For patent tuberculosis the author recommands a four drugs therapy (isoniazide, rifampicine, ethambutol, pyrazinamide) for 2 months (3 months in case of hematogenous dissemination with acute miliary or meningitis) followed by a two drugs regimen (isoniazide, rifampicine) for 4 to 9 months. Corticosteroids are indicated when atelectasis resulting from bronchial obstruction is present.